EP 3327019 A4 20190403 - HETEROCYCLIC COMPOUND
Title (en)
HETEROCYCLIC COMPOUND
Title (de)
HETEROCYCLISCHE VERBINDUNG
Title (fr)
COMPOSÉ HÉTÉROCYCLIQUE
Publication
Application
Priority
- JP 2015143353 A 20150717
- JP 2016070936 W 20160715
Abstract (en)
[origin: EP3327019A1] The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I) : wherein each symbol is as defined in the specification, or a salt thereof.
IPC 8 full level
A61K 31/4245 (2006.01); A61K 31/427 (2006.01); A61K 31/437 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); C07D 413/04 (2006.01)
CPC (source: EP US)
A61K 31/4035 (2013.01 - EP US); A61K 31/4245 (2013.01 - EP US); A61K 31/427 (2013.01 - EP US); A61K 31/437 (2013.01 - EP US); A61K 31/4439 (2013.01 - EP US); A61K 31/444 (2013.01 - EP US); A61P 25/28 (2017.12 - EP US); C07D 413/04 (2013.01 - EP US); C07D 413/14 (2013.01 - EP US); C07D 417/14 (2013.01 - EP US); C07D 471/04 (2013.01 - EP US)
Citation (search report)
- No further relevant documents disclosed
- See references of WO 2017014170A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
EP 3327019 A1 20180530; EP 3327019 A4 20190403; JP WO2017014170 A1 20180426; US 10357484 B2 20190723; US 2019008836 A1 20190110; WO 2017014170 A1 20170126
DOCDB simple family (application)
EP 16827730 A 20160715; JP 2016070936 W 20160715; JP 2017529869 A 20160715; US 201615745290 A 20160715